secwatch.observer — SEC 8-K summary
======================================

Issuer:     TherapeuticsMD, Inc. (TXMD)
CIK:        0000025743
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0001213900-25-042663
Event type: earnings
Sentiment:  neutral
Materiality: 0.25
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TherapeuticsMD Q1 net loss narrows to $636K; license revenue up 26%
-------------------------------------------------------------------

- Net loss from continuing ops $(636)K ($0.06/sh) vs $(809)K ($0.07/sh) in Q1 2024.
- License revenue $393K, up 25.8% from $313K, driven by Mayne License sales changes.
- Operating expenses $1,264K, down 13.1% from prior year on royalty business efficiencies.
- Cash and equivalents $5.7M at March 31, 2025; no debt disclosed.
- Company continues evaluating strategic alternatives including M&A or asset sale.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/25743/000121390025042663/0001213900-25-042663-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/25743/000121390025042663/ea0241986-8k_therap.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-042663

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer